Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Baptist Health South Florida
- Study ID
- NCT03430791
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab 240 mg IV — DRUGNivolumab IV 240mg IV every 2 weeks for maximum of 24 months.
- Nivolumab 3 mg/kg — DRUGNivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.
- Ipilimumab 1 mg/kg — DRUGIpilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.
- NovoTTF200A (Optune) — DEVICEA device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
Study Details
Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.
Key Dates
- Start date
- Dec 5, 2018
- Status verified
- Nov 2022
- Primary completion
- May 29, 2020
- Completion
- Jan 27, 2021
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Nivolumab MonotherapyNivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months
- Experimental: Nivolumab+IpilimumabNivolumab 3 mg/kg IV with ipilimumab then 240 mg every 2 weeks for maximum of 24 months. Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. NovoTTF200A (Optune) TTF for maximum 24 months
Primary Outcome Measure
Objective Response Rate According to Modified iRANO Criteria [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | - |
Find similar trials in Miami, FL
By condition
By specialty
By research site
Related Studies
- Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsPHASE1 · Recruiting · Sabine Mueller, MD, PhD · Birmingham, Alabama
- Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent GlioblastomaRecruiting · University of Miami · Miami, Florida
- A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMPHASE1 · Recruiting · Boston Scientific Corporation · Birmingham, Alabama
- Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBMPHASE3 · Recruiting · CarThera · Phoenix, Arizona